ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Construction In Progress : HK$36.06 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is ImmuneOnco Biopharmaceuticals (Shanghai) Construction In Progress?

ImmuneOnco Biopharmaceuticals (Shanghai)'s quarterly construction in progress declined from Dec. 2022 (HK$36.08 Mil) to Jun. 2023 (HK$0.00 Mil) but then increased from Jun. 2023 (HK$0.00 Mil) to Dec. 2023 (HK$36.06 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai)'s annual construction in progress increased from Dec. 2021 (HK$20.28 Mil) to Dec. 2022 (HK$36.08 Mil) but then declined from Dec. 2022 (HK$36.08 Mil) to Dec. 2023 (HK$36.06 Mil).

ImmuneOnco Biopharmaceuticals (Shanghai) Construction In Progress Historical Data

The historical data trend for ImmuneOnco Biopharmaceuticals (Shanghai)'s Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuneOnco Biopharmaceuticals (Shanghai) Construction In Progress Chart

ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data

Trend

Dec21

Dec22

Dec23

Construction In Progress

20.28

36.08

36.06

ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Construction In Progress	20.28	-	36.08	-	36.06

ImmuneOnco Biopharmaceuticals (Shanghai) Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuneOnco Biopharmaceuticals (Shanghai) Inc (HKSE:01541) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

1000 Zhangheng Road, Unit 15, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, CHN

Website

http://cn.immuneonco.com

ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has developed a rich pipeline of 14 drug candidates with eight ongoing clinical programs, featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.

Executives

Gba Fund Investment Limited	2101 Beneficial owner
Jia Xing Han Ning Qi Ye Guan Li You Xian Gong Si	2201 Interest of corporation controlled by you
Halo Biomedical Lp	2201 Interest of corporation controlled by you
Halo Biomedical Investment Ii Limited	2101 Beneficial owner
Halo Biomedical Investment I Limited	2201 Interest of corporation controlled by you
Tian Wenzhi	2501 Other
Lav Immon Hong Kong Limited	2101 Beneficial owner
Greater Bay Area Homeland Investments Limited	2201 Interest of corporation controlled by you
Greater Bay Area Homeland Development Fund (gp) Limited	2201 Interest of corporation controlled by you
Ho Yao
Lav Immuneonco Hong Kong Limited	2101 Beneficial owner
Lav Gp V, L.p.	2201 Interest of corporation controlled by you
Lav Corporate V Gp, Ltd.	2201 Interest of corporation controlled by you
Lav Biosciences Fund V, L.p.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you

ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Headlines

No Headlines